China Biologic, a leading fully integrated plasma-based biopharmaceutical company in China has received the Good Manufacturing Practice (GMP) certification from China Food and Drug Administration (CFDA) in respect of its plasma production facility at its Guizhou subsidiary.
Mr. David (Xiaoying) Gao, Chairman and Chief Executive Officer of China Biologic, commented, "We are delighted to receive GMP certification earlier than expected, allowing us to resume full-scale commercial production in late March for all of our approved plasma products, including the newly approved human prothrombin complex concentrate (PCC). This concludes our efforts of the past nine months to achieve full compliance with GMP standards at our Guizhou facility. We attribute this achievement to the massive contributions of our Guizhou employees, who completed comprehensive facility upgrading ahead of schedule. We expect higher growth with more products available for sales starting in the third quarter this year, due to lag effects from long production cycles and CFDA approval procedures for each batch of products."
Mr. Gao continued, "With these comprehensive upgrades, we are confident we can enhance the operating efficiency of our Guizhou facility to meet growing market demand moving forward."
Source: PR Newswire
Click here for the complete issue.